Hypertension

Panelists discuss how antihypertensive treatment encompasses multiple drug classes with distinct mechanisms of action, alongside lifestyle modifications such as dietary changes and exercise, providing a comprehensive approach to blood pressure management.

Panelists discuss how antihypertensive treatment encompasses multiple drug classes with distinct mechanisms of action, alongside lifestyle modifications such as dietary changes and exercise, providing a comprehensive approach to blood pressure management.

Panelists discuss how traditional antihypertensive medications face challenges including adverse reactions, complex dosing regimens, and variable efficacy across different patient populations, which can limit their therapeutic success.

Panelists discuss how poor medication adherence and comorbidities such as chronic kidney disease (CKD) contribute to uncontrolled hypertension despite the availability of numerous treatment options, highlighting key challenges in achieving effective blood pressure management.

Our Cardiology Month in Review for November 2024 spotlights the approval of acoramidis and top content from AHA 2024.

In this episode, hosts break down a pair of studies from AHA 2024, BPROAD and SUMMIT, as well as a study in JAMA projecting semaglutide eligibility in US adults.

Viet Le, PA-C, DMSc, breaks down new data and updates from AHA 24, spotlighting 3 specific trials and the applicability of artificial intelligence in care.

Once-daily aprocitentan is indicated to help lower blood pressure in adult patients with hypertension who are inadequately controlled on other medications.

The Pressure Check study at Yale aims to address disparities in blood pressure management.

The HCPLive Cardiology month in review for September 2024 spotlights ESC Congress 2024, Family Heart Global Summit, pipeline updates, and more!

In this episode, John Giacona, PhD, PA-C, shares insights from the 2024 AHA Hypertension Scientific Sessions, focusing on primary aldosteronism and renal denervation.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from the European Society of Cardiology (ESC) Congress 2024.

The August 2024 cardiology month in review highlights critical data from the European Society of Cardiology Congress 24 and the latest updates on finerenone.

The STOP-or-NOT trial found similar outcomes for continuation or discontinuation of RAS inhibitors before noncardiac surgery, supporting individualized decision-making.

On August 19, 2024, Liquidia Corporation announced the FDA's tentative approval of treprostinil inhalation powder for adults with PAH and PH-ILD.

A recent study found that noise exposure of power looms (≥ 85 decibels) puts workers at risk of their overall blood pressure increasing.

A study cautions the AHA's new PREVENT equations may underprescribe statins and antihypertensives, potentially causing 107,000 more ASCVD events in 10 years.

In this episode, John Buse, MD, PhD, discusses the background, expected prevalence, reaction to results, and the importance of the second part of the CATALYST trial.

Individuals with both psoriasis and hypertension have approximately a 2-fold increased mortality risk, which is greater than the mortality risk for psoriasis or hypertension alone.

At Heart in Diabetes, full results of the GRACE trial detailed the benefits of relacorilant use from both parts of the 2-part, phase 3 trial.

Relacorilant achieves primary endpoint in phase 3 GRACE trial among patients with hypercortisolism and hyperglycemia, hypertension or both, with sNDA expected in Q3 2024.

Swapnil Hiremath, MD, MPH, explains the importance of 24-hour ambulatory blood pressure monitoring (ABPM) to rule out the possibility of white coat hypertension.

Matthew Nudy, MD, discusses a trio of meta-analyses examining the effects of intensive blood pressure control on various targets.

A recap of the biggest FDA news and decisions in cardiovascular medicine from the first 3 months of 2024, with commentary on recent announcements by Deepak Bhatt, MD, MPH, MBA.